One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.
Fiche publication
Date publication
février 2016
Journal
Transplantation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DUCLOUX Didier
Tous les auteurs :
Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B, Ducloux D, Chatelet V, Moulin B, Freguin C, Hazzan M, Lang P, Legendre C, Merville P, Mourad G, Mousson C, Pouteil-Noble C, Purgus R, Rerolle JP, Sayegh J, Westeel PF, Zaoui P, Boivin H, Le Gouge A, Lebranchu Y
Lien Pubmed
Résumé
Treatment of acute antibody-mediated rejection (AMR) is based on a combination of plasma exchange (PE), IVIg, corticosteroids (CS), and rituximab, but the place of rituximab is not clearly specified in the absence of randomized trials.
Mots clés
Acute Disease, Adult, Biomarkers, blood, Biopsy, Creatinine, blood, Double-Blind Method, Female, France, Glomerular Filtration Rate, drug effects, Graft Rejection, diagnosis, Graft Survival, drug effects, Humans, Immunosuppressive Agents, adverse effects, Kidney, drug effects, Kidney Transplantation, adverse effects, Male, Middle Aged, Prospective Studies, Recovery of Function, Rituximab, adverse effects, Time Factors, Treatment Outcome
Référence
Transplantation. 2016 Feb;100(2):391-9